Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) is one of 255 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Finch Therapeutics Group to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.
Earnings and Valuation
This table compares Finch Therapeutics Group and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Finch Therapeutics Group||$18.53 million||-$58.16 million||-1.16|
|Finch Therapeutics Group Competitors||$773.46 million||$147.16 million||0.03|
This is a summary of current recommendations and price targets for Finch Therapeutics Group and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Finch Therapeutics Group||0||0||1||0||3.00|
|Finch Therapeutics Group Competitors||1632||5697||11338||209||2.54|
Finch Therapeutics Group currently has a consensus target price of $17.00, suggesting a potential upside of 662.33%. As a group, “Biological products, except diagnostic” companies have a potential upside of 121.59%. Given Finch Therapeutics Group’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Finch Therapeutics Group is more favorable than its rivals.
Volatility & Risk
Finch Therapeutics Group has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group’s rivals have a beta of 0.76, meaning that their average stock price is 24% less volatile than the S&P 500.
This table compares Finch Therapeutics Group and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Finch Therapeutics Group||-313.84%||-26.15%||-23.87%|
|Finch Therapeutics Group Competitors||-3,821.16%||-65.50%||-29.75%|
Institutional & Insider Ownership
22.7% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 53.5% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 17.0% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Finch Therapeutics Group beats its rivals on 7 of the 13 factors compared.
Finch Therapeutics Group Company Profile (Get Rating)
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.